These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28834401)

  • 1. Neutrophils, G-CSF and their contribution to breast cancer metastasis.
    Mouchemore KA; Anderson RL; Hamilton JA
    FEBS J; 2018 Feb; 285(4):665-679. PubMed ID: 28834401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy.
    Pentheroudakis G; Malamou-Mitsi V; Briasoulis E; Damala K; Vassou A; Vartholomatos G; Kolaitis N; Pavlidis N
    Cancer; 2004 Oct; 101(8):1767-75. PubMed ID: 15386335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.
    Coffelt SB; Kersten K; Doornebal CW; Weiden J; Vrijland K; Hau CS; Verstegen NJM; Ciampricotti M; Hawinkels LJAC; Jonkers J; de Visser KE
    Nature; 2015 Jun; 522(7556):345-348. PubMed ID: 25822788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dark side of granulocyte-colony stimulating factor: a supportive therapy with potential to promote tumour progression.
    Yeo B; Redfern AD; Mouchemore KA; Hamilton JA; Anderson RL
    Clin Exp Metastasis; 2018 Apr; 35(4):255-267. PubMed ID: 29968171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic growth instructed by neutrophil-derived transferrin.
    Liang W; Li Q; Ferrara N
    Proc Natl Acad Sci U S A; 2018 Oct; 115(43):11060-11065. PubMed ID: 30301793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-1β Blockade Attenuates Thrombosis in a Neutrophil Extracellular Trap-Dependent Breast Cancer Model.
    Gomes T; Várady CBS; Lourenço AL; Mizurini DM; Rondon AMR; Leal AC; Gonçalves BS; Bou-Habib DC; Medei E; Monteiro RQ
    Front Immunol; 2019; 10():2088. PubMed ID: 31552036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer.
    de Gast GC; Vyth-Dreese FA; Nooijen W; van den Bogaard CJ; Sein J; Holtkamp MM; Linthorst GA; Baars JW; Schornagel JH; Rodenhuis S
    J Clin Oncol; 2002 Jan; 20(1):58-64. PubMed ID: 11773154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo effects of granulocyte colony-stimulating factor on neutrophils in glycogen storage disease type 1B: granulocyte colony-stimulating factor therapy corrects the neutropenia and the defects in respiratory burst activity and Ca2+ mobilization.
    McCawley LJ; Korchak HM; Douglas SD; Campbell DE; Thornton PS; Stanley CA; Baker L; Kilpatrick L
    Pediatr Res; 1994 Jan; 35(1):84-90. PubMed ID: 7510873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of polymorphonuclear neutrophils (PMNs) in clearance of granulocyte colony-stimulating factor (G-CSF) in vivo and in vitro.
    Ericson SG; Gao H; Gericke GH; Lewis LD
    Exp Hematol; 1997 Dec; 25(13):1313-25. PubMed ID: 9406990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophils drive accelerated tumor progression in the collagen-dense mammary tumor microenvironment.
    García-Mendoza MG; Inman DR; Ponik SM; Jeffery JJ; Sheerar DS; Van Doorn RR; Keely PJ
    Breast Cancer Res; 2016 May; 18(1):49. PubMed ID: 27169366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological and clinical correlates after chemotherapy and granulocyte colony-stimulating factor administration.
    Higa GM; DeVore RF; Auber ML; Lynch JP; Landreth KS
    Pharmacotherapy; 1998; 18(1):1-8. PubMed ID: 9469674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of granulocyte colony stimulating factor on neutrophil functions in children with neutropenia after chemotherapy in the course of neoplasma.
    Czygier M; Dakowicz Ł; Szmitkowski M
    Adv Med Sci; 2007; 52():143-6. PubMed ID: 18217407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.
    Sugawara Y; Fisher SJ; Zasadny KR; Kison PV; Baker LH; Wahl RL
    J Clin Oncol; 1998 Jan; 16(1):173-80. PubMed ID: 9440740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo administration of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor increases neutrophil oxidative burst activity.
    Wiltschke C; Krainer M; Nanut M; Wagner A; Linkesch W; Zielinski CC
    J Interferon Cytokine Res; 1995 Mar; 15(3):249-53. PubMed ID: 7584671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with Granulocyte-colony Stimulating Factor (G-CSF) is not associated with Increased Risk of Brain Metastasis in Patients with
    Fujii T; Rehman H; Chung SY; Shen J; Newman J; Wu V; Hines A; Azimi-Nekoo E; Fayyaz F; Lee M; Raptis G; Egeblad M; Zhu X
    J Cancer; 2021; 12(18):5687-5692. PubMed ID: 34405029
    [No Abstract]   [Full Text] [Related]  

  • 17. Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis.
    Aarts MJ; Vriens BE; de Boer M; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Tol J; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; van der Rijt CCD; Smilde TJ; van der Velden AW; Peer N; Tjan-Heijnen VCG
    Oncology; 2017; 93(5):323-328. PubMed ID: 28848182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer.
    Silber JH; Fridman M; Shpilsky A; Even-Shoshan O; Smink DS; Jayaraman J; Fox KR; Pauly MV
    J Clin Oncol; 1998 Jul; 16(7):2435-44. PubMed ID: 9667261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.
    Kennedy MJ; Davis J; Passos-Coelho J; Noga SJ; Huelskamp AM; Ohly K; Davidson NE
    Cancer Res; 1993 Nov; 53(22):5424-8. PubMed ID: 7693341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.